These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 34402466)
21. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518 [TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373 [TBL] [Abstract][Full Text] [Related]
23. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531 [TBL] [Abstract][Full Text] [Related]
24. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302 [TBL] [Abstract][Full Text] [Related]
25. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808 [TBL] [Abstract][Full Text] [Related]
26. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB. Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043 [TBL] [Abstract][Full Text] [Related]
27. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S; Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801 [TBL] [Abstract][Full Text] [Related]
28. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084 [TBL] [Abstract][Full Text] [Related]
33. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339 [TBL] [Abstract][Full Text] [Related]
34. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797 [TBL] [Abstract][Full Text] [Related]
35. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. Chaparro M; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Hernández-Breijo B; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Bermejo F; Beltrán B; Rodríguez Pescador A; Banales JM; Olivares D; Aguilar-Melero P; Menchén L; Ferreiro-Iglesias R; Blazquez Gomez I; Benítez García B; Guijarro LG; Marin A; Bernardo D; Gisbert JP; Eur J Gastroenterol Hepatol; 2020 May; 32(5):588-596. PubMed ID: 32251204 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360 [TBL] [Abstract][Full Text] [Related]
38. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G; J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637 [TBL] [Abstract][Full Text] [Related]
39. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824 [TBL] [Abstract][Full Text] [Related]
40. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]